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Abstract: The diagnosis of fungal Neglected Tropical Diseases (NTD) is primarily based on initial
visual recognition of a suspected case followed by confirmatory laboratory testing, which is often
limited to specialized facilities. Although molecular and serodiagnostic tools have advanced,
a substantial gap remains between the desirable and the practical in endemic settings. To explore this
issue further, we conducted a survey of subject matter experts on the optimal diagnostic methods
sufficient to initiate treatment in well-equipped versus basic healthcare settings, as well as optimal
sampling methods, for three fungal NTDs: mycetoma, chromoblastomycosis, and sporotrichosis.
A survey of 23 centres found consensus on the key role of semi-invasive sampling methods such
as biopsy diagnosis as compared with swabs or impression smears, and on the importance of
histopathology, direct microscopy, and culture for mycetoma and chromoblastomycosis confirmation
in well-equipped laboratories. In basic healthcare settings, direct microscopy combined with clinical
signs were reported to be the most useful diagnostic indicators to prompt referral for treatment.
The survey identified that the diagnosis of sporotrichosis is the most problematic with poor sensitivity
across the most widely available laboratory tests except fungal culture, highlighting the need to
improve mycological diagnostic capacity and to develop innovative diagnostic solutions. Fungal
microscopy and culture are now recognized as WHO essential diagnostic tests and better training in
their application will help improve the situation. For mycetoma and sporotrichosis, in particular,
advances in identifying specific marker antigens or genomic sequences may pave the way for new
laboratory-based or point-of-care tests, although this is a formidable task given the large number of
different organisms that can cause fungal NTDs.
Keywords: fungal NTDs; laboratory diagnosis; mycetoma; sporotrichosis; chromoblastomycosis;
integrated approaches
1. Introduction
In 2016, the World Health Organisation (WHO) [1] formally recognized mycetoma as a neglected
tropical disease (NTD). Mycetoma is a chronic subcutaneous infection caused by over fifteen different
species of fungi or filamentous bacteria (actinomycetes) [2,3], and advanced cases often involve bone
penetration and relentless destruction and swelling of tissue. Mycetoma can cause substantial disability
and in some cases, may prove fatal. In 2017, the equally disfiguring mycosis chromoblastomycosis [4],
caused by over 8 different fungal species, was added to the list of WHO-recognized NTDs. This
disease causes massive limb swelling, accompanied in some patients by verrucous skin plaques
and when left untreated, may cause secondary squamous cell carcinoma. Both mycetoma and
chromoblastomycosis are now classified by WHO as fungal NTDs, together with other unspecified
deep mycoses. One of these unspecified mycoses meeting many of the criteria for an NTD is
sporotrichosis, another subcutaneous fungal infection that shares features with both mycetoma and
chromoblastomycosis including comparative neglect and disproportionate impact on impoverished
populations. Over the past ten years, sporotrichosis has spread widely in Brazil, to the south and south
east of the country from its origins as a zoonotic infection spread from cats in Rio de Janeiro state [5].
Although mycetoma, chromoblastomycosis, and sporotrichosis are different diseases, they share
several features. Firstly, they are largely confined to the tropics and affect poor communities, usually
in rural areas [6]. In most of the endemic regions, these infections occur sporadically, although in some
areas they reach a much higher level of endemicity. For example, the large ongoing Brazilian outbreak
is linked to contact with infected cats and largely caused by the species Sporothrix brasiliensis [5].
In other parts of the world, foci of infection not associated with cats are more common and these are
usually caused by different species such as S. schenckii (sensu strictu), or S. globosa [7]. Mycetoma
occurs worldwide across a region called the global mycetoma belt, which covers tropical countries
with low annual rainfall in Africa, Asia, and the Americas. Some localities within these countries
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report higher incidence of infection (e.g., Sudan and Mexico), although surveillance is limited and
true incidence is unknown [2,3]. Mycetoma differs from the other two NTDs in that some endemic
areas report a majority of cases caused by actinomycete bacteria rather than fungi, but both bacterial
and fungal etiologies result in similarly severe physical and social disabilities including stigma and
loss of economic productivity. Strictly speaking eumycetoma caused by fungi is the only true fungal
NTD. However, WHO currently classifies both actinomycetoma and eumycetoma under the heading
of fungal NTDs or skin NTDs (see below). In chromoblastomycosis hot spots of infection occur in
countries with areas of higher annual rainfall including Madagascar, Costa Rica, Brazil, the Dominican
Republic, and parts of the state of KwaZulu Natal in South Africa [4]. All three conditions are treated
using a process known as innovative and intensified disease management (IDM), which provides
antifungal or surgical treatment based on the needs and clinical expression of disease in each individual
patient [3]. However, many current antifungals have limited effectiveness and although there are case
studies indicating promising activity for some, e.g., voriconazole and posaconazole [8], there are very
few formal clinical trials, and because of relative cost, even with the introduction of generic medications,
medicines are not available to all who need them. No new medicines for these infections have been
introduced in the last 10 years. A new international clinical trial of the antifungal fosravuconazole is
underway for mycetoma due to M.mycetomatis, but a long journey remains to achieve effective and
affordable treatment options.
The responsibility for the initial recognition of these three fungal and skin NTDs often falls on
front line health service workers who have received simple basic training. However, the differential
diagnosis includes important and complex diseases, such as cutaneous leishmaniasis and mycobacterial
infections, as well as tumours and chronic inflammatory dermatoses. Moreover, the appearance of
these diseases may be quite different in people living with HIV. Confirmatory laboratory diagnoses
depend on specialized medical mycology techniques and expertise. Thus, many cases are probably
missed because of a lack of mycological capacity at front line health care centres and peripheral
diagnostic laboratories.
All three of these infections present clinically with visible, skin abnormalities [9–11], which raises
the possibility and underscores the importance of rapid diagnosis. With rapid diagnosis would come
faster and more accurate treatment decisions. To begin addressing the need for better and faster
diagnosis, a new WHO handbook provides a simple guide for early clinical diagnosis [12]. However,
because treatment of fungal NTDs is both lengthy and complex, diagnosis needs to be confirmed in
the laboratory. Yet, there is no simple, accurate test akin to a smear for leprosy, card antigen test in
lymphatic filariasis and yaws, or molecular identification in Buruli ulcer [11]. Furthermore, consensus
is lacking on the best method to confirm fungal NTD diagnoses.
For this reason, a group of clinicians, microbiologists, and mycologists with expertise in the
diagnosis of mycetoma, chromoblastomycosis, and sporotrichosis have put forward a consensus
on (a) the current optimal or gold standard methods to diagnosis these diseases in well-equipped
laboratories and (b) advice on the best methods that can support the diagnosis in resource-limited
conditions where access to specialized laboratory facilities is limited. We also provide advice on best
practices for obtaining diagnostic specimens.
2. Methods
Twenty-six experienced mycologists and clinicians, including dermatologists and infectious
disease specialists, recognized for their laboratory or clinical expertise in mycetoma, sporotrichosis,
and chromoblastomycosis from different world regions were invited to participate in this survey;
of these, 23 responded and completed the assessment. Those who participated included some from
endemic regions as well as others from non-endemic zones, but the latter all had extensive practical
experience of these diseases in endemic areas. Survey questions included descriptions of current
practice in well-equipped diagnostic or clinical settings in each respondent’s country. In addition,
questions covered confirmatory tests that could be used in peripheral clinics or laboratories with
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little expertise in mycological techniques. The best methods of obtaining diagnostic specimens were
also discussed
Questions on confirmatory tests included direct microscopy after treatment with 10–20% potassium
hydroxide and culture on suitable laboratory media such as Sabouraud’s dextrose agar. Other methods
included serology and histopathology with special stains such as periodic acid Schiff reagent or
methenamine silver. Molecular diagnostic tests were also included, such as probe-based Polymerase
Chain Reaction (PCR) techniques, sequencing, and Matrix Assisted Laser Desorption/Ionisation
Time of Flight (MALDI-ToF). In addition, participants were asked to indicate where other diagnostic
or assessment tools were useful to support the management of patients. These included imaging
methods such as Magnetic Resonance Imaging (MRI), ultrasound and other point-of-care tests such as
dermoscopy (in situ microscopy of the skin).
Results were collated and presented to members of the group in a workshop where the choices of
diagnostic methods were clarified and refined further to reach an overall consensus
3. Results
3.1. Well-Equipped Clinical Centres and Laboratories
There was significant agreement on the optimal Fungal NTD diagnostic methods in the
well-equipped settings. For instance, >83% of respondents agreed on the use of clinical features and
culture mycetoma, chromoblastomycosis, and sporotrichosis (Table 1).
Table 1. Optimal diagnostic methods in a well provided laboratory—positive responses.
Disease ClinicalFeatures
Direct
Microscopy Culture Serology
Molecular
Diagnosis Histopathology Other
Mycetoma 92% 88% 96% 8% 71% 88% imaging,dermoscopy
Chromoblastomycosis 88% 92% 96% 8% 50% 92% dermoscopy
Sporotrichosis 83% 25% 1 96% 4% 50% 67%
intradermal
test
1 The importance of microscopic features in Sporotrichosis diagnosis elicited a qualified response (see below).
For mycetoma > 88% recommended the combined use of direct microscopy (Figure 1a,b), culture
and histopathology (Figure 2a,b) together with clinical evaluation. While respondents recognized the
increasing importance of molecular diagnostic tests, such as specific probe-based PCR and sequencing,
these are not yet available in all settings. There was also a high degree of support for the use of imaging,
MRI, X-ray, or ultrasound as important adjuncts to diagnosis of mycetoma particularly for planning
management strategies.
Trop. Med. Infect. Dis. 2019, 4, x FOR PEER REVIEW 4 of 10 
 
Polymerase Chain Reaction (PCR) techniques, sequencing, and Matrix Assisted Laser 
Desorption/Ionisation Time of Flight (MALDI-ToF). In addition, participants were asked to indicate 
where other diagnostic or assessment tools were useful to support the management of patients. These 
included imaging methods such as Magnetic Resonance Imaging (MRI), ultrasound and other point-
of-care tests such as dermoscopy (in situ microscopy of the skin). 
Results were collated and presented to members of the group in a workshop where the choices 
of diagnostic methods were clarified and refined further to reach an overall consensus 
3. Results 
3.1. Well-Equipped Clinical Centres and Laboratories 
There was significant agreement on the optimal Fungal NTD diagnostic methods in the well-
equipped settings. For instance, > 83% f respondents agre  on the use of clinical features and 
culture mycetoma, chromoblastomycosis, and sporotrichosis (Table 1). 
Table 1. Optimal diagnostic methods in a well provided laboratory—positive responses. 
Disease 
Clinical  
Features 
Direct  
Microscopy 
Culture Serology 
Molecular  
Diagnosis 
Histopathology Other 
Mycetoma 92% 88% 96% 8% 71% 88% 
imaging,  
dermoscopy 
Chromoblastomycosis 88% 92% 96% 8% 50% 92% dermoscopy 
Sporotrichosis 83% 25% 1 96% 4% 50% 67% 
intradermal 
test 
1 The importance of microscopic features in Sporotrichosis diagnosis elicited a qualified response (see below). 
For mycetoma > 88% recommended the combined use of direct microscopy (Figure 1a,b), culture 
and histopathology (Figure 2a,b) together with clinical evaluation. While respondents recognized the 
increasing importance of molecular diagnostic tests, such as specific probe-based PCR and 
sequencing, these are not yet available in all settings. There was also a high degree of support for the 
use of imaging, MRI, X-ray, or ultrasound as important adjuncts to diagnosis of mycetoma 
particularly for planning management strategies. 
 
Figure 1. (a) Direct microscopy (15%) potassium hydroxide (KOH)). Dark grain eumycetoma (fungal 
mycetoma) × 40; (b) Direct microscopy (15% KOH). Pale grain actinomycetoma due to Nocardia 
brasiliensis × 40. 
a b 
Figure 1. (a) Direct microscopy (15%) potassium hydroxide (KOH)). Dark grain eumycetoma
(fungal mycetoma) × 40; (b) Direct microscopy (15% KOH). Pale grain actinomycetoma due to
Nocardia brasiliensis × 40.
Trop. Med. Infect. Dis. 2019, 4, 122 5 of 11
Trop. Med. Infect. Dis. 2019, 4, x FOR PEER REVIEW 5 of 10 
 
 
Figure 2. (a) Surgical biopsy. Dark grain of eumycetoma M.mycetomatis (Haematoxylin eosin HE) × 
40; (b) Deep biopsy. Grain of Nocardia brasiliensis (HE) × 40.  
There was similar agreement in chromoblastomycosis where over 88% recommended the use of 
direct microscopy (Figure 3a), histopathology (Figure 3b), and culture with clinical features. There 
was less support for the use of molecular diagnostic tests (50%) but their use is evolving. Although 
dermoscopy has not been widely used in the diagnosis of chromoblastomycosis, some advocated for 
its value as a point of care test. 
 
Figure 3. (a) Direct microscopy skin scales (15% KOH). Muriform cells typical of 
Chromoblastomycosis; (b) Skin biopsy. Muriform cells of chromoblastomycosis (HE) × 40. 
With Sporotrichosis, responses were more specific, with culture as the most favored diagnostic 
option (96%) together with some clinical features; most respondents specified lymphangitic spread 
as a hallmark clinical feature. Half of respondents advocated for the use of molecular tests for the 
diagnosis of sporotrichosis and species-level identification. Certain Sporothrix species have unique 
epidemiologic characteristics, and thus unique and public health implications and species-level 
identification can only be achieved by molecular methods. However, the frequent absence of 
organisms detectable either by direct microscopy or histopathology presents a major challenge to 
sporotrichosis laboratory confirmation. In discussion, some expressed the view that microscopy and 
histopathology were useful in order to exclude clinically similar infections such as cutaneous 
leishmaniasis, but all agreed that these two laboratory procedures were ancillary and could not be 
recommended for primary diagnosis. Imaging is sometimes useful in widespread Sporotrichosis to 
exclude internal dissemination. 
3.2. Peripheral Clinics and Laboratories 
When asked about the use of diagnostic procedures in resource-limited field settings where 
access to a well-equipped laboratory was unlikely, responses were different. Nonetheless, there was 
a b 
a b 
Figure 2. (a) Surgical biopsy. Dark grain of eumycetoma M.mycetomatis (Haematoxylin eosin HE) × 40;
(b) Deep biopsy. Grain of Nocardia brasiliensis (HE) × 40.
There was similar agreement in chro last ycosis where over 88% recommended the use of
direct microsc py (Figure 3a), histopathol igure 3b), and culture with clinic l features. There
was les support for the use of molecular di tic tests (50%) but their u e is e olving. Alt ough
dermoscopy has not been widely used in the diagnosis of chromoblastomycosis, some advocated for
its value as a point of care test.
Trop. Med. Infect. Dis. 2019, 4, x FOR PEER REVIEW 5 of 10 
 
 
Figure 2. (a) Surgical biopsy. Dark grain of eumycetoma M.mycetomatis (Haematoxylin eosin HE) × 
40; (b) Deep biopsy. Grain of Nocardia brasiliensis (HE) × 40.  
There was similar agreement in chromoblastomycosis where over 88% recommended the use of 
direct microscopy (Figure 3a), histopathology (Figure 3b), and culture with clinical features. There 
was less support for the use of molecular diagnostic tests (50%) but their use is evolving. Although 
dermoscopy has not been widely used in the diagnosis of chromoblastomycosis, some advocated for 
its value as a point of care test. 
 
Figure 3. (a) Direct microscopy skin scales (15% KOH). Muriform cells typical of 
Chromoblastomycosis; (b) Skin biopsy. Muriform cells of chromoblastomycosis (HE) × 40. 
With Sporotrichosis, responses were more specific, with culture as the most favored diagnostic 
option (96%) together with some clinical features; most respondents specified lymphangitic spread 
as a hallmark clinical feature. Half of respondents advocated for the use of molecular tests for the 
diagnosis of sporotrichosis and species-level identification. Certain Sporothrix species have unique 
epidemiologic characteristics, and thus unique and public health implications and species-level 
identification can only be achieved by molecular methods. However, the frequent absence of 
organisms detectable either by direct microscopy or histopathology presents a major challenge to 
sporotrichosis laboratory confirmation. In discussion, some expressed the view that microscopy and 
histopathology were useful in order to exclude clinically similar infections such as cutaneous 
leishmaniasis, but all agreed that these two laboratory procedures were ancillary and could not be 
recommended for primary diagnosis. Imaging is sometimes useful in widespread Sporotrichosis to 
exclude internal dissemination. 
3.2. Peripheral Clinics and Laboratories 
When asked about the use of diagnostic procedures in resource-limited field settings where 
access to a well-equipped laboratory was unlikely, responses were different. Nonetheless, there was 
a b 
a b 
Figure 3. (a) Direct microscopy skin scales (15% KOH). Murif rm cells typical of Chromoblastomycosis;
(b) Skin biopsy. Muriform cells of chromoblastomycosis (HE) × 40.
With Sporotrichosis, resp ns s were more specific, with culture as the most f vored diagnostic
option (96%) together with some clinical features; most respondents specified lymphangitic spread as a
hallmark clinical feature. Half of respondents advocated for the use of molecular tests for the diagnosis
of sporotrichosis and species-level identification. Certain Sporothrix species have unique epidemiologic
characteristics, and thus unique and public health i plications and species-level identification can
only be achieved by molecular methods. However, the frequent abse ce of organisms detectable
either by d rect micr scop or histopathology presents a majo challenge to sporotrichosis l boratory
confirmation. In discussion, some expressed the view that microscopy and histopathology were useful
in order to exclu e clinicall similar infections uch as cutan ous leishmani sis, but all agreed that
these two laboratory procedures were ancillary and could not be recommended for primary diagnosis.
Imaging is sometimes useful in widespread Sporotrichosis to exclude internal dissemination.
3.2. Peripheral Clinics and Laboratories
When asked about the use of diagnostic procedures in resource-limited field settings where
access to a well-equipped laboratory was unlikely, responses were different. Nonetheless, there was
considerable agreement on a minimum diagnostic set that includes clinical feature evaluation (Table 2).
All recognized that culture-based diagnosis was seldom available away from main centres.
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Table 2. Diagnostic methods of use in peripheral clinics and laboratories (positive results).
Disease ClinicalFeatures
Direct
Microscopy Culture Serology
Molecular
Diagnosis Histopathology Other
Mycetoma 96% 88% 33% - 13% 43% imaging
Chromoblastomycosis 96% 92% 33% 8% 4% 54%
Sporotrichosis 88% 42% 50% 4% 45 21%
For mycetoma, clinical features (96%) coupled with direct microscopy (88%) were favored by
respondents as diagnostics that should trigger referral to a well-equipped reference laboratory. Similar
agreement on the value of these same two methods was also reported for chromoblastomycosis.
Experts disagreed on the use of histopathology for both mycetoma and chromoblastomycosis. The crux
of this disagreement stemmed from the recognition that capacity for histopathological diagnosis differs
widely in certain areas, including in resource-limited setting [13]. Ultimately, all agreed that, where
capacity exists, histopathology is an important primary diagnostic test.
Results differed for sporotrichosis. At least half of respondents reported that the simplest of
laboratory tests available at peripheral levels (i.e., direct microscopy) are unhelpful for sporotrichosis
diagnosis, and that histopathology should not be prioritized. As reported for well-equipped settings,
respondents felt that direct microscopy and histopathology were primarily useful for excluding similar
clinical syndromes such as cutaneous leishmaniasis and not for positively identifying sporotrichosis.
For direct microscopy, the requirement of special stains (e.g., Giemsa stain) to identify and rule out
Leishmaniasis as a diagnosis is an additional obstacle for small clinics. Therefore, these tests are not
helpful in guiding referrals to expert centres and were not recommended for front line sporotrichosis
diagnosis. Sample collection methods (Table 3).
Table 3. Method of collecting material for laboratory investigation (positive responses).
Responders Choice
Swab from
Broken Skin
or Sinuses
Impression
Smear
Skin Scraping
from Broken
Skin or Sinuses
Punch or
Incision Biopsy
or Curettage
Excision
Biopsy
Mycetoma 38% 42% 54% 74% 61%
Chromoblastomycosis 8% 29% 67% 79% 42%
Sporotrichosis 21% 17% 50% 75% 58%
For most participants, superficial sampling, such as swabbing, or impression smears, were not
useful for the diagnosis of these three NTDs. Removing tissue material by scraping the surface
where it is broken and moist, or preferably, by incision or excision and deep biopsy or curettage
were the preferred methods among 58–79% of the respondents. The majority (67%) support for skin
scraping in chromoblastomycosis reflects the fact that, provided that the correct site (where small
black dots can be seen on the skin surface) is selected, the characteristic pigmented “muriform” cells
of chromoblastomycosis can be seen with direct microscopy in skin surface scrapings, as the fungal
cells are eliminated trans-epidermally. On discussion it was agreed that the best site to obtain these
is the surface of the lesion where there are dark areas (black spots), that indicate where clusters of
pigmented cells are present. For sporotrichosis, Sporothrix species are detected in culture from skin
lesion samples in the first 7 to 8 days of incubation although most (78%) supported the use of material
taken by curettage or biopsy. Taking deeper tissue samples may be a rate-limiting step in accessing
laboratory supported diagnosis in resource-limited environments as this process requires equipment
such biopsy punches or curettes, together with local anesthetic, which are often not available in local
primary care settings.
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4. Discussion
Our survey and subsequent discussions identified areas of strong agreement on the best practices
for confirming fungal NTD diagnoses. This consensus provides a framework for improving diagnostic
selection, defining referral pathways, and improving access to laboratories with the appropriate capacity.
The disparity between recommendations for well-equipped and resource-limited settings was telling.
Where experts agreed on use of “older” diagnostic methods such as culture and microscopy, the primary
rational was based on practicality and available resources. Survey respondents acknowledged the
substantial advances in new diagnostic methods for fungal NTDs and their increasingly important
roles in typing and speciation, in spite of limited access to date in endemic areas.
Concerted efforts have been made to improve field diagnosis in remote settings through
comprehensive and simple training methods, largely based on visual clues to diagnosis [12]. But adapting
or developing new diagnostic tests, drawing on the results of recent research was identified as a critical
need for the future. For mycetoma, important recent developments with direct impact on diagnosis
include molecular methods to identify new etiologic agents, isothermal amplification techniques,
the adaptation of MALDI Tof to fungal identification and the finding of novel infection-related
antigens [14–17]. A new grading system for Magnetic Resonance Imaging (MRI) allows clinicians
to assess extent and severity of mycetoma, which may not be apparent on visual inspection [18].
The challenge of adapting new tests to in endemic areas are considerable, but these modalities are
sorely needed. A recent survey of communities in an endemic zone for mycetoma in Sudan shows
the benefits of active case finding, but also the non-specific nature of current diagnostic definitions
based on clinical signs and symptoms, used at community level, which leads to the identification of
many false positive cases [19]. The dermatoscopic features and diagnostic utility of pale grain [20] and
dark grain mycetomas have been described [21] and with validation, may prove a viable point-of-care
diagnostic indicator. Although dermoscopy was not a component of our survey, it appeared repeatedly
in discussion. A major obstacle to wider use of dermoscopy is the required training and cost of the
dermatoscope. These obstacles have been overcome for chromoblastomycosis diagnostics with the use
of molecular and MALDI ToF analyses [22–24]. Chromoblastomycosis may present in a number of
morphological forms ranging from shallow plaques, to verrucous plaques, sinuses, and ringworm-like
lesions, and improving the accuracy of diagnosis is a key target [25,26]. Again, dermoscopy is a
possible point of care option in settings where there are health care workers trained in its use. However,
the dermatoscopic features of chromoblastomycosis are not well recognized among those working
in this field. For example, while clusters of golden/brown structures in the skin are indicative of
pigmented fungal cells [27], other features are non-specific, and distinguishing useful features must
be learned.
The clinical presentations of sporotrichosis are notoriously pleomorphic which presents an
obstacle to translation into usable visual clues for diagnosis, for use at field level, and some cases
are complicated by additional distractors such as secondary immunological reactions, erythema
nodosum, and erythema multiforme [28,29]. In addition, sporotrichosis presents a diagnostic challenge,
although more accurate molecular tools have begun to change our understanding of the importance of
identifying the newly identified species in terms of transmission and treatment strategies [7,30–32].
There have also been major advances in identifying antigens associated with infection [33]. An ELISA
assay has been used in one retrospective study of patients with sporotrichosis and yielded promising
results [34]; serological detection is associated with at least two specific antigens in the cell wall of
Sporothrix species [35] and building on this work may provide new options for diagnosis. There is
also a commercial latex agglutination test for the detection of antibodies to Sporothrix, although in
cutaneous disease antibody titres are not high and false positive reactions at low titre have also been
recorded. Nonetheless, there are formidable difficulties in accurately recognizing sporotrichosis in
peripheral settings, as the hallmark clinical features of Sporotrichosis such as lymphangitic spread
are common to other pathogens, such as Leishmania, which often share the same endemic areas [36].
Direct microscopic examination or histopathology of cases of sporotrichosis are of often of little value
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as there are usually very few organisms seen, although the presence of a refractile eosinophilic fringe
or asteroid body in sporotrichosis, where it can be found, is a very useful laboratory diagnostic sign.
Culture remains the most used laboratory diagnostic test where this is available. Screening suspected
cases with an intradermal skin test antigen test is one possible diagnostic option that could be applied
in peripheral settings [37], but the reagents are not widely available and skin reactions may also be
positive in exposed but uninfected individuals. The dermatoscopic appearances of sporotrichosis
have also been reported [38] but similar dermatoscopic appearances are also seen in other systemic
mycoses disseminating to the skin such as cryptococcosis or histoplasmosis which limits its diagnostic
use [39]. Accurate laboratory diagnostic tests are available for these latter two systemic mycoses.
From a practical standpoint those diseases that may manifest a lymphangitic pattern of spread such
as sporotrichosis, cutaneous leishmaniasis, non-tuberculous mycobacterial infection, and nocardiosis
all require special treatment. As an indicator for referral to a specialized facility, a chain of skin
lumps suggesting lymphangitic spread, as a clinical sign, is worth considering as part of a diagnostic
algorithm. However, it does not address confirmation of the diagnosis in other clinical presentations
of sporotrichosis.
Survey respondents were selected for their expertise in both clinical and laboratory diagnostic
approaches to fungal NTDs, and many also have training and experience in well-equipped settings in
developed countries. Often, however, clinicians and laboratories in endemic areas are not familiar
with these procedures. Likewise, they have little access to newer diagnostic techniques including
molecular diagnostics. Experience and competency is often limited, in technical clinical procedures
such as performing a skin biopsy safely with local anesthetic and in diagnostic techniques such as
direct microscopy and histopathology of fungal disease. As a start to mitigating the impact of limited
resources on capacity, a free online training module has been launched recently by the Fungal Infection
Trust (www.microfungi.net), and may contribute to improving such skills, but there remain large
gaps. The World Health Organisation, together with subject specialists, is in the process of addressing
these needs through the promotion of a skin NTD initiative [40], which specifically includes the
fungal infections.
Although there are some examples of new laboratory tests that may simplify the diagnostic journey
of the patient presenting with the fungal NTDs mycetoma, chromoblastomycosis and sporotrichosis,
there is a real and urgent need for innovation in diagnostics. The development of accurate antigen
detection tests for any of these diseases would dramatically change diagnostic access and performance,
particularly if available for use at the point of care. For mycetoma specifically, a field-ready serologic
assay that can distinguish the fungal variant of mycetoma from the visually similar bacterial variant
could prevent patients from receiving incorrect and ineffective treatments. However, diagnosis to
species level would require a formidable array of different tests given the large number of different
species that cause mycetoma. A similar qualification applies to chromoblastomycosis. The modification
of molecular techniques for use at the peripheral laboratory level is a second option with great potential
impact subject to the same concerns about the large number of different potential causes. For now, small
steps are also worth the effort [41]. For example, supplementing simple visual diagnostic methods [12]
with information key characteristics such as lymphangitic spread of skin lesions could improve
specificity in a clinically relevant way. In addition, a simple training guide on direct microscopy in
small hospital settings would improve diagnostic capacity for mycetoma and chromoblastomycosis.
For many years, mycologists have lamented the limited availability of simple, accurate and specific
laboratory tests, yet almost all attention has focused on the invasive infections of the severely
immunocompromised, such as invasive aspergillosis. However, there is an urgent need to improve
existing technologies for the diagnosis of the fungal NTDs seen in resource poor settings, in order to
reduce the burden of these debilitating diseases.
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